Shelton Capital Management Has $5.45 Million Position in DexCom, Inc. $DXCM

Shelton Capital Management cut its position in DexCom, Inc. (NASDAQ:DXCM) by 3.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,419 shares of the medical device company’s stock after selling 2,222 shares during the period. Shelton Capital Management’s holdings in DexCom were worth $5,449,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Andra AP fonden acquired a new stake in DexCom during the 2nd quarter worth $26,000. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the first quarter worth about $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom during the first quarter worth about $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom during the 2nd quarter valued at about $45,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of DexCom in the 2nd quarter valued at approximately $70,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. The Goldman Sachs Group cut their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Wells Fargo & Company set a $93.00 price objective on shares of DexCom and gave the company an “overweight” rating in a research report on Friday, October 31st. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. TD Cowen dropped their price target on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $84.00 price objective on shares of DexCom in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $86.73.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $63.52 on Tuesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a market cap of $24.77 billion, a PE ratio of 44.11, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The business’s 50 day moving average price is $64.19 and its two-hundred day moving average price is $75.60. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the prior year, the firm posted $0.45 EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other news, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the sale, the director directly owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 9,999 shares of company stock worth $619,391. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.